Glucagon-like peptide-1 (GLP-1) agonists and chronic weight management are two of the hottest topics in the health care industry. There isn’t nearly enough content devoted to weighing all the variables associated with them, which is an issue our clinical experts aim to address.

In this episode of the Pharmacy Friends podcast, “Weight management — A holistic journey,” Prime Therapeutics/Magellan Rx Management (Prime/Magellan Rx) experts discuss our four primary tenets of practice for chronic weight management and how they play a role in ensuring any recommendations are rooted in evidence, focus on improving patient adherence and persistence to treatment, and drive value.

Maryam Tabatabai, PharmD, vice president of clinical information n at Prime/Magellan Rx, hosts this episode, joined by Pat Gleason, PharmD, BCPS, FCCP, FAMCP, assistant vice president of health outcomes at Prime/Magellan Rx and Dariush Mozaffarian, M.D., DrPH, Tufts University.

“The new real-world evidence that we’ve been a part of generating here at Prime Therapeutics has shown that at year one for your third of individuals still appear to be taking their GLP-1 and then at two years, most recently, only 1 in 7, or 15%, are still on therapy,” Gleason said.

Pharmacy Friends is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming and, most importantly, what it means to you. Listen to the full episode “Weight management — A holistic journey,” on primetherapeutics.com/pharmacy-friends.

Listen now